Cholesterol lowering in atherosclerosis

American Journal of Cardiology

Volumn 86, Issue 4 SUPPL. 2, 2000, Pages 29H-34H

  Brown, W Virgil ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; ATORVASTATIN; COLESTYRAMINE; ENALAPRIL; FLUINDOSTATIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; WARFARIN;

ARTERY DIAMETER; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0034710701     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)01097-3     Document Type: Article

References (19)

1. The second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 89:1994;1329-1445.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad base of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
4. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C.-C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
5. Ballantyne C.M. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol. 82:(suppl):1998;3Q-12Q.
6. Pedersen T.R. Aggressive lipid-lowering therapy a clinical imperative . Eur Heart J. 19:(suppl M):1998;M15-M21.
7. Schwartz G.G., Oliver M.F., Ezekowitz M.D., Ganz P., Waters D., Kane J.P., Texter M., Pressler M.L., Black D., Chaitman B.R., Olsson A.G. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol. 81:1998;578-581.
8. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass graft. N Engl J Med. 336:1997;153-162.
9. Popma J.J., Sawyer M., Selwyn A.P., Kinlay S. Lipid lowering therapy after coronary revascularization the interventionalist's perspective . Am J Cardiol. 86:(suppl):2000;18H-28H.
10. Pitt B., Waters D., Brown W.V., van Boven A.J., Schwartz L., Title L.M., Eisenberg D., Shurzinske L., McCormick L.S. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease Atorvastatin versus Revascularization Treatment Investigators . N Engl J Med. 341:1999;70-76.
11. Buller C.E., Dzavik V., Taylor D.A., Plante S., Burton J.R., Tymchak W.J., Catellier D., Montague T.J., Teo K.K. Relationship of changes in cholesterol levels and progression of coronary atherosclerosis in patients with normal cholesterol the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) (abstract 956) . Circulation. 100:1999;I185.
12. Burton J.R., Tymchak W.J., Dzavik V., Taylor D.A., Buller C.E., Plante S., Catellier D., Montague T.J., Teo K.K. Progressors and regressors changes in coronary atherosclerosis with lipid lowering therapy: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) (abstract 957) . Circulation. 100:1999;I185.
13. Nissen S.E. Rational for a postintervention continuum of care insights from intravascular ultrasound . Am J Cardiol. 86:(suppl):2000;12H-17H.
14. Pearson T.A., Laurora I., Chu H., Kafonek S. The Lipid Treatment Assessment Project (L-TAP) a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals . Arch Intern Med. 160:2000;459-467.
15. Frolkis J.P., Zyzanski S.J., Schwartz J.M., Suhan P.S. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation. 98:1998;851-855.
16. Marcelino J.J., Feingold K.R. Inadequate treatment with HMG-CoA reductase inhibitors by care providers. Am J Med. 100:1996;605-610.
17. Jones P.H., Kafonek S., Laurora I., Hunninhake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol. 81:1998;582-587.
18. Edmundowicz D., Andrews T.C., Shear C.L. Comparing treatment success with statins results from the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS) (abstract) . J Am Coll Cardiol. 35:(suppl A):2000;314A.
19. Hunninghake D., Bakker-Arkema R.G., Wigand J.P., Drehobl M., Schrott H., Early J.L., Abdallah P., McBride S., Black D.M. Treating to meet NCEP-recommended LDL cholesterol guidelines with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract. 47:1998;349-356.